Home › RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
 

Keywords :   


RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?

2015-09-11 14:41:16| Biotech - Topix.net

Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.

Tags: is it market million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
More »